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Abstract
Background: The design of new healthcare schemes which involve using molecular HPV screening means that
both persistence and clearance data regarding the most prevalent types of HR-HPV occurring in cities in Colombia
must be ascertained.
Methods: This study involved 219 HPV positive women in all of whom 6 types of HR-HPV had been molecularly
identified and quantified; they were followed-up for 2 years. The Kaplan-Meier survival function was used for calculating
the time taken for the clearance of each type of HPV. The role of a group of independent variables concerning the time
taken until clearance was evaluated using a Cox proportional-hazards regression model or parametric (log-logistic)
methods when necessary. Regarding viral load, the Wilcoxon rank-sum test was used for measuring the difference of
medians for viral load for each type, according to the state of infection (cleared or persistent). The Kruskal-Wallis test
was used for evaluating the change in the women’s colposcopy findings at the start of follow-up and at the end of it
(whether due to clearance or the end of the follow-up period).
Results: It was found that HPV-18 and HPV-31 types had the lowest probability of becoming cleared (1.76 and 2.75 per
100 patients/month rate, respectively). Women from Colombian cities other than Bogotá had a greater probability of
being cleared if they had HPV-16 (HR 2.58: 1.51–4.4 95% CI) or HPV-58 (1.79 time ratio: 1.33-2.39 95% CI) infection.
Regarding viral load, HPV-45-infected women having 1 × 106 to 9.99 × 109 viral copies had better clearance compared
to those having greater viral loads (1.61 time ratio: 1.01-2.57 95% CI). Lower HPV-31 viral load values were associated
with this type’s persistence and changes in colposcopy findings for HPV-16 gave the worst prognosis in women having
low absolute load values.
Conclusions: HPV infection clearance in this study was related to factors such as infection type, viral load and the
characteristics of the cities from which the women came. Low viral load values would indicate viral persistence and a
worse prognosis regarding a change in colposcopy findings.
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Background
Persistent infection with high-risk human papillomavirus
(HR-HPV) types is the main (but not the only) cause of
developing pre-cancerous lesions or cervical cancer [1-3].
Several types of HPV considered oncogenic have been
found to be responsible for around 90% of cancer cases
worldwide [3], having high HR-HPV type prevalence
rates (i.e. HPV-16, −31, −18, −33, −45 and −58) amongst
Colombian women [4]. Our group is aware that multiple
infections are of great importance for our population,
since more than 40% prevalence has been reported in
some regions of the country [4].
It has been described that HPV infection represents a
transient phenomenon throughout the whole world,
leading to high infection prevalence, even though most
cases do not produce cervical lesions and those which
do, consist of low grade lesions involving spontaneous
regression [5]. However, Colombia does have a high
cervical cancer incidence rate and high morbidity-
mortality values for a type of cancer which is highly
preventable [6,7].
Intrinsic viral determinants, such as the infecting viral
type or viral load, have been identified as HPV persistence
markers [1,8,9]; however, some socio-environmental fac-
tors also play an important role in this type of infection
and its possible outcomes [5,10].
The present work seeks to describe both viral and host
factors which could be intervening in the persistence
and clearance of the most common HR-HPV types in
Colombia. This study was mainly aimed at providing
epidemiological information illustrating how HPV in-
fection can become eliminated in a target population,
bearing the state of the infection (single or multiple)
and the most prevalent HR-HPV types in mind.
Methods
Study population and ethical considerations
Women eligible for the present study were voluntarily
attending cervical screening consultations in three
Colombian cities (Chaparral, Girardot and Bogotá) be-
tween April 2007 and March 2010.
The present study involved 3 cities: Bogotá the country’s
capital having an urban population, Chaparral located
in the Tolima department is mainly inhabited by mesti-
zos leading a sedentary life style and Girardot in the
Cundinamarca department which has become a tourist
destination due to its favourable weather and closeness
to Bogotá. Data concerning Chaparral and Girardot
was combined in a single category called “other city” to
ensure a better analysis of women in this study, as both
these cities are small, having similar climates and lying
at less than 1,000 masl (Bogotá is 2,600 masl).
As inclusion criteria, all women signed a written
informed consent form and completed a questionnaire
regarding their sociodemographic characteristics, sexual
behaviour and risk factor data before undergoing a gynae-
cological examination and providing a cervical smear sam-
ple. The signature of a parent or guardian was required
for females younger than 18 years old. Women who stated
that they did not intend to move from their home cities
for at least 2 years after the study began were included in
the follow-up study.
Amongst exclusion criteria considered, women who
had negative HPV results, those whose samples had little
DNA in them (to ensure that all PCR assays were per-
formed satisfactorily) or no amplification for the HMBS
gene were not included. Women who were pregnant at
base line and who had less than 3 months or more than
9 months until their next visit were also excluded from
the study.
The Papanicolaou test was used for analysing samples
and HPV–DNA detection; real-time PCR was used for
selecting just HPV positive women. This study was su-
pervised and approved by the relevant ethics’ committees
at Hospital de Engativá Nivel II (in Bogotá), Hospital
San Juan Bautista (in Chaparral in the Tolima depart-
ment) and Nuevo Hospital San Rafael (in Girardot in the
Cundinamarca department).
HPV DNA collection, processing and detection by PCR
amplification
Cervical samples were collected with a cytobrush and
kept in 95% ethanol at 4°C [11]. DNA from these samples
was purified using a commercial Quick Extract Solution
kit, following the manufacturer’s instructions. Samples
were homogenised in 200 μL lysis buffer (10 mM Tris–HCl
(pH 7.9), 0.45% Nonidet- P-40, 0.45% Tween 20 and
60 mg/mL proteinase K) and incubated for 6 min at 65°C,
followed by 2 min at 92°C. Samples were centrifuged at
13,000 rpm for 10 min and the supernatant was removed
and stored at 20°C.
Polymerase chain reaction (PCR) for human β-globin
was carried out on samples to check DNA integrity
using GH20/PC04 primers [12]. Three HPV generic
primer sets were used for HPV-DNA detection, as de-
scribed in previous studies (i.e. GP5+/GP6+, MY09/MY11
and pU1M/2R) [13].
Viral load determined by real-time PCR
Primers and probes
Specific primers for each viral type and for Homo sapiens
hydroxymethylbilane synthase (HMBS) were synthesised
according to a study published by Moberg et al., [14]. The
primers described by Moberg et al., amplified the same
region for HPV-33 and −58; a new set of primers aimed at
the E7 region of these viral types was thus designed. De-
signing probes for each viral type and HMBS was based
on four parallel duplex real-time PCRs per patient, taking
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into account the types included in each reaction (Table 1)
and support by integrated DNA technologies.
Cloning and sequencing
Processed samples were used as template for PCR
(10 μL final volume), containing 0.5 U/μL Mango Taq
DNA polymerase (Bioline), 1× Mango Taq Color reaction
Buffer, 2 mM MgCl2, 250 nM dNTPs, 1 mM of each pri-
mer and DNase-free water to fulfil the necessary reaction
volume. The PCR protocol for each fragment consisted of
initial denaturing for 5 min at 95°C, followed by 35 cycles
of 30 s at 95°C, 20 s at corresponding melting temperature
and 30 s at 72°C. A reaction containing DNA-free water
was used as negative control. The amplicons so obtained
were purified with a Wizard PCR preps kit (Promega),
once their quality has been evaluated on 3.25% agarose
gel. A TOPO TA cloning kit was used for ligation,
followed by transformation in TOP10 E. coli cells (Invitro-
gen). Several clones which grew on selective LB plates
with 50 μg/mL kanamycin were incubated in LB broth at
37°C with 250 rpm overnight. Recombinant plasmids were
purified using an UltraClean mini plasmid prep kit (MO
BIO laboratories, California, USA) and sequenced with an
automatic ABI PRISM 310 Genetic Analyzer (PE Applied
Biosystems, California, USA). Each insert’s integrity was
checked by aligning the products with the respective
theoretical sequenced fragments of each gene using
Clustal W software [15].
Real-time PCR
A NanoDrop 2000 (Thermo Scientific NanoDrop Products)
was used for quantifying plasmid DNA and the DNA copy
numbers were calculated by using the URI Genomics and
Sequencing Center web site [16] (Table 1). Standardised
RT-PCR assays with 10-fold serial plasmid dilutions
(1011-106copies) gave a standard curve for each viral
type and HMBS gene (−3.2 to −3.5 slope values). Samples
were tested for HPV-16, HPV-18, HPV-31, HPV-33, HPV-
45 and HPV-58. The human HMBS (hydroxymethylbilane
synthase) gene was amplified in all samples to verify DNA
integrity and calculate viral copy number per cell. PCR in-
volved using a CFX96 Touch Real-Time PCR detection
system which can detect 6 different fluorescent dyes; four
real-time PCR reactions were carried out per sample, one
for detecting HPV-16, a second for HPV-18 and −31, a
third for HPV-33 and −45 and a fourth one for HPV-58
and HMBS.
The HPV-16 PCR mix contained 1× reaction buffer,
1.5 mM MgCl2, 250 nM of each dNTP, 250 nM of each
primer, 1.5 U/μL MangoTaq Polymerase (Bioline) and
500 nM probe. The second PCR mix for HPV-18
and −31 consisted of 1× reaction buffer, 2 mM MgCl2,
275 nM of each dNTP, 500 nM HPV-18 primers, 250
nM HPV 31 primers, 1.5 U/μL MangoTaq polymerase
and 500 nM of each probe. The HPV-33 and −45 PCR
mix included 1× reaction buffer, 1.75 mM MgCl2, 275
nM of each dNTP, 250 nM HPV-33 primers, 500 nM
HPV-45 primers, 1.5 U/μL MangoTaq polymerase and
500 nM of each probe. The last PCR mix for HMBS
and HPV58 contained 1× reaction buffer, 1.87 mM
MgCl2, 250 nM of each dNTP, 500 nM of each primer,
1.5 U/μL MangoTaq polymerase, 200 nM HMBS probe
and 500 nM HPV 58 probe. All real-time PCR reac-
tions contained 2 μL of the DNA extracted from each
Table 1 Primers and probes used for qPCR
Region Viral type Primer sequence 5′ - 3′ mT* Plasmid product quantification qPCR test Probe Probe size (bp) Quencher
E7 HPV-16 AGCTCAGAGGAGGAGGAT 54 1.43E1012 Reaction 1 FAM 78 ZEN/Iowa
Black FQ
GGTTACAATATTGTAATGGGCTC
E1 HPV-18 CATTTTGTGAACAGGCAGAGC 53.7 1.19E1012 Reaction 2 Cy5 80 IBRQ
ACTTGTGCATCATTGTGGACC
E6 HPV-31 ACGATTCCACAACATAGGAGGA 53.7 1.35E1012 HEX 78 ZEN/lowa
Black FQ
TACACTTGGGTTTCAGTACGAGGT
E7 HPV-33 ATTAAGTGACAGCTCAGATGA 53.7 1.86E1012 Reaction 3 FAM 78 ZEN/Iowa
Black FQ
ACATAAACGAACTGTGGTGTT
E1 HPV-45 CCATTTGTGAACAGGCAGAGC 53.7 1.59E1012 Cy5 76 IBRQ
CAACACCTGTGCATCATTCTGA
E7 HPV-58 CGAGGATGAAATAGGCTTGG 53.7 1.23E1012 Reaction 4 HEX 109 ZEN/Iowa
Black FQ
ACACAAACGAACCGTGGCGT
HMBS GCCTGCAGTTTGAAATCAGTG 53.7 1.98E1012 FAM 76 ZEN/Iowa
Black FQ
CGGGACGGGCTTTAGCTA
HPV Human papillomavirus, mT Melting temperature in °C, FAM 6-carboxyfluorescein, Cy5 FluoroLink Mono Reactive Dye Cy5, HEX Hexachlorofluoresceine, HMBS,
Hydroxymethylbilane synthase.
*Melting temperature for quantitative real-time PCR.
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cervical sample and DNA-free water to complete 20 μL
volume.
96-well plates were used for each run, including 6
standards for each viral type and HMBS, involving 10-fold
plasmid dilutions (1011-106 copy dynamic detection range)
and a no template control to rule out DNA contamination.
The thermal cycling conditions for HPV-18, −31, −33,
−45, −58 and HMBS consisted of initial denaturing for
5 min at 94°C, followed by 30 amplification cycles for
10 s at 94°C and 30 s at 53.7°C. Initial HPV-16 denatur-
ing was followed by 30 PCR cycles for 30 s at 54°C and
30 s at 94°C.
Viral load values were given as absolute and normal-
ised. The viral load was normalised to cellular DNA in-
put amount, using the following formula: viral load
(HPV copies/cell): number of HPV copies/(number of
HMBS copies/2) [17].
Statistical analysis
Women who had had both a Pap-smear result and
HPV-DNA detected by PCR and who fulfilled the
follow-up inclusion criteria (at least 3 follow-ups, leaving
6 to 9 months between visits) were included in the ana-
lysis. Women were excluded where the HMBS gene was
not amplified by RT-PCR. Analysis was based on type-
specific HPV infection rather than on individual women,
taking into account that multiple infection is common in
the Colombian population [4].
Cox’s multivariate regression model was used when
calculating sample size; hazard ratios (HR) of at least 2
were thus considered, whenever they had a 5% signifi-
cance level, 80% power, 0.55 standard deviation of tested
covariates and 0.1 correlations between tested covariates.
The probability of clearance was set at 0.7, according to
previous reports [18,19]. Such suppositions required
sample size of at least 86 women. STATA 12 stpower
command was used for making the calculations.
Clearance was defined as at least two consecutive
type-specific HPV DNA samples proving negative,
such samples taken at 6-month intervals following a
positive sample [20]. Persistence was defined as the
identification of the same HPV type in baseline and
follow-up samples [21]. The time taken for HR-HPV
infection clearance was calculated in months (95% CI),
estimated using the Kaplan-Meier survival function.
The first step was evaluating each variable independ-
ently to assess their importance regarding clearance time
(Table 2); those variables having a significance level of
less than 0.2 in the univariate analysis were included in
the multivariable models.
The independent variables included in the multivariable
model were city, ethnicity, age of first sexual relationship,
number of lifetime sexual partners, family planning
method, coinfection and viral load (categorised as low,
viral load being lower than 9.99E + 5, middle viral load
between 1.00E + 6 to 9.99E + 9 and high viral load being
higher than 1.00E + 10) concerning time taken to clear-
ance using a Cox’s proportional hazard (PH) regression
model or parametric methods (log-logistic) when the PH
assumption was violated. The PH assumption was graph-
ically evaluated using log-log plots and a PH test based on
weighted residuals using Grambsch and Therneau tests
[22]. The choice of parametric model was defined using
Akaike information criterion (AIC) and Bayesian informa-
tion criterion (BIC).
Three categories were assigned to the variable “changes
in colposcopy” (alike, improved and worsened) for evalu-
ating changes in colposcopy findings between the results
of colposcopy at the start of follow-up and the end of it
(whether due to clearance of the virus or not). The
Kruskall-Wallis test was used for evaluating the difference
in viral load for each viral type and change in colposcopy
findings since the sample did not have a normal distribu-
tion. The Mann–Whitney test was also used for evaluating
viral load according to the state of infection (persistent or
cleared).
Categorical variable distribution amongst groups was
assessed by Chi-squared test or Fisher’s test, as appropriate.
Median and interquartile ranges were used for quantitative
variables, according to the data distribution. Incidence
ratios were estimated using months of follow-up as de-
nominator. A ≤ 0.05 p value was considered statistically
significant; STATA 12 was used for all statistical analysis.
Results
The present work has consolidated data concerning 219
women infected by several HR-HPV types; they became
voluntarily incorporated into our follow-up study. All
the women included guaranteed to attend a base-line
visit and at least 3 follow-up visits with around 6 month
difference (±3 months); 23.3% of the population being
sampled managed to attend follow-up 4 (i.e. data became
available from 5 visits).
Regarding baseline information, 23.7% (n = 52: 18.3-29.9
95% CI) of the women in the study were infected by a
single type of HR-HPV (single infection); the rest of the
population, 76.3% (n = 167) had multiple infections, dis-
tributed as follows: 26% (n = 57: 20.3-32.4 95% CI) had
infections having simultaneous detection for 2 types of
HR-HPV, 29.7% (n = 65: 23.7-36.2 95% CI) infection by
3 types of HR-HPV, 13.2% (n = 29: 9.1-18.4 95% CI) had
positive identification for 4 viral types, 5% (n = 11: 2.5-8.8
95% CI) were infected by 5 high risk types and 2.3% (n =
5: 1–5.2 95% CI) had viral DNA identification for 6 types
of HR-HPV.
Participants’ age ranged from 17 to 71 years-old (SD 10.8,
mean 42.2 years). Most of the participating population
was mestizo (98.2%; n = 215: 95.4-99.5 95% CI), and from
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Table 2 Baseline characteristics’ distribution according to HPV infection stage
Baseline characteristics Single HPV infection n = (%) Multiple HPV infection n = (%) Total p =
Age (y) (n = 219) <30 10 (31.25 ) 22 (68.75) 32 0.54
30-50 31 (22.96) 104 (77.04) 135
>50 11 (21.15 ) 41 (78.85) 52
Origin (n = 219) Bogota 21 (30.43) 48 (69.57) 69 0.115
Other cities 31 (20.67) 119 (79.33) 150
No. of family members living
together (n = 219)
<=4 35 (24.65 ) 107 (75.35) 142 0.670
>4 17 (22.08 ) 60 (77.92) 77
*Average monthly income (n = 219) Minimum 30 (20.98) 113 (79.02) 143 0.243
>minimum 22 (28.95) 54 (71.05) 76
Ethnicity (n = 219) Indigenous 0 1 (100) 1 1
Mestizo 52 (24.19) 163 (75.81) 215
Afro-descendant 0 3 (100) 3
Marital status (n = 219) Married 2 (14.29) 12 (85.71) 14 0.849
Divorced 1 (33.33) 2 (66.67) 3
Single 1 (20) 4 (80) 5
Living with partner 48 (24.49) 148 (75.51) 196
Widow 0 1 (100) 1
Healthcare scheme affiliation (n = 219) Contributory 6 (35.3) 11 (64.70) 17 0.244
Subsidised 46 (22.77) 156 (77.23) 202
Age on first intercourse (n = 219) <18 22 (23.66) 71 (76.34) 93 0.979
≥18 30 (23.81) 96 (76.19) 126
Lifetime sexual partners (n = 219) 1 25 (24.51) 77 (75.49) 102 0.804
>1 27 (23.08) 90 (76.92) 117
Contraceptive method (n = 219) No method used 25 (27.78) 65 (72.22) 90 0.470
Surgery 14 (21.21) 52 (78.79) 66
Hormonal 3 (13.04) 20 (86.96) 23
Barrier 10 (25) 30 (75) 40
Number of pregnancies (n = 219) None 2 (50) 2 (50) 4 0.07
1-2 25 (28.09) 64 (71.91) 89
3-4 15 (16.13) 78 (83.87) 93
>4 10 (30.3) 23 (69.7) 33
Abortions (n = 158) None 23 (28.05) 59 (71.95) 82 0.481
1 11 (20) 44(80) 55
> = 2 4 (19.05) 17 (80.95) 21
STD (n = 210) No 37 (22.16) 130 (77.84) 167 0.112
Yes 15 (34.88) 28 (65.12) 43
Colposcopy results (n = 202) L-SIL 14 (29.17) 34 (70.83) 48 0.819
H-SIL 0 1 (100) 1
Negative 37 (24.18) 116 (75.82) 153
Cytological findings (n = 219) ASC-US 1 (11.11) 8 (88.89) 9 0.840
L-SIL 3 (25) 9 (75) 12
Negative 48 (24.24) 150 (75.76) 198
HPV Human papillomavirus, p= P value, STD Sexually-transmitted diseases, ASCUS Atypical squamous cells of undetermined significance, SIL Squamous intraepithelial
lesions. Some variables had lower values due to loss of data regarding self-completed questionnaires.
*The minimum average monthly income in Colombia is about US$ 300.
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the city of Girardot (66.2%; n = 145: 59.6-72.4 95% CI).
The population’s socio-demographic and sexual behaviour
data was described regarding follow-up (base-line), ac-
cording to the state of the infection (single infection or
multiple infections; Table 2).
Survival data was estimated for each type of HR-HPV
regardless of single infection or multiple infections and
clearance time for each type (Figure 1). A greater clearance
occurred for HPV-33-infected women, followed by
HPV-16-infected females, whilst fewer events per month
occurred for HPV-18- and HPV-31-infected women
(Table 3).
Figure 2 clearly shows that HPV-18 infection was the
most persistent; infection had not become resolved in 15
women 2 years later, followed by HPV-31 which was
present in 4 women having positive identification for
Figure 1 Kaplan-Meier plots of time taken to HPV infection clearance for the 6 HR-HPV types studied here.
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Table 3 Prevalence, reinfection and clearance rates concerning the 6 HR-HPV types
Viral type Baseline Clearance Reinfection
Prevalence% (n=)
[95% CI]
Viral load, median (IQR) Rate*
[95% CI]
Total HPV viral load**, median (IQR) % (n=)
[95% CI]
Viral load, median (IQR)
Absolut Normalised Absolut Normalised Absolut Normalised
HPV-16 71.2% (156) [64.7-77.1] 2.9E + 6 (9.7E + 6) 0.2 (6.7) 5.9 [4.9-7.2] 2.17E + 09 (7.67E + 10) 5 (13,468) 48.6% (53) [39–58] 2.9E + 6 (9.2E + 6) 0.32 (5.3)
HPV-18 53% (116) [46.1-59.7] 4.3E + 6 (4.56E + 07) 0.42 (13) 1.76 [1.3-2.4] 6.56E + 09 (6.34E + 11) 208 (30,101) 12% (7.4-20.4) 3.0E + 6 (4.28E + 07) 0 .1 (1.8)
HPV-31 37% (81) [30.6-43.8] 9.04E + 07 (6.29E + 09) 44 (3,360) 2.75 [1.96-3.84] 1.23E + 07 (3.02E + 07) 7 (96) 50% (17) [32–67] 1.96E + 09 (7.61E + 09) 3,360 (12,400)
HPV-33 6.4% (14) [3.5-10.5] 2.96E + 07 (1.14E + 09) 3.6 (39,100) 11.51 [6.7-19.8] 1.39E + 9 (1.91E + 10) 774 (4,683) 38.5% (5) [14–68] 1.47E + 08 (5.82E + 08) 51 (128)
HPV-45 43.4% (95) [36.7-50.2] 2.48E + 06 (1.12E + 09) 0.33 (180) 5 [3.9-6.42] 1.84E + 08 (9.30E + 11) 18 (1E + 05) 43.5% (27) [30.9-56.7] 1.14E + 08 (1.94E + 09) 17 ( 7,180)
HPV-58 45.7% (100) [38.9-52.5] 6.14E + 05 (2.1E + 06) 0.4 (15.7) 4.05 [3.1-5.24] 4.35e + 08 (5.92e + 10 ) 141 (5,749) 0 0*** 0
*Clearance rates are given in values per month, per 100 individuals.
**Total HPV viral load was taken as the mean of the other HPV type infections on clearance.
***The load for other HPV-58 types was not calculated as there was no re-infection.





















this type during each follow-up visit (infection remaining
unresolved by the end of the study).
Specific viral load type values were also determined in
this study; Table 3 gives both absolute and normalised
viral load values for each type infections at the start of
the study. It is worth highlighting that those infected by
HPV-31 had the highest viral load values, even those
normalised by the number of cells, whilst HPV-16 gave
the lowest viral load values.
Hazard ratios were calculated for two (HPV-16 and-18)
of the 4 most prevalent viral types in molecular determin-
ation (i.e. HPV-16, −18, −45, −58), bearing in mind the
most important variables in univariate models, for each
type (data not shown) (Table 4). Time ratios were cal-
culated for the remaining types, since these (HPV-45
and −58) did not comply with supposed proportional
risks for the aforementioned variables; variables could
not thus be re-categorised nor could they be assumed
to be time-dependent variables. Regression was thereby
modelled using a parametric model, bearing in mind the
shape of the hazard function and AIC and BIC. The log-
logistic model gave the best fit for both types with the
foregoing criteria.
Multivariate model values showed that the probability
of clearance when a woman had HPV-16 or HPV-58
infection became significantly increased in women from
another city compared to women living in the capital.
It is worth stating that both types belong to the same
species (A9).
Regarding the types belonging to species A7, HPV-18
infection did not have a statistically significant association
with any variable evaluated here. However, it was observed
that the probability of clearance regarding HPV-45 be-
came significantly increased when the absolute viral load
for this type ranged from 1 × 106 to 9.99 × 109 compared
to loads equal to or greater than 1 × 1010.
It should be highlighted that single or multiple HR-HPV
infection was not associated with time to clearance in the
present sample, since coinfection values for any HPV type
were not statistically significant in this model (Table 4).
When evaluating the medians for normalised viral load
(per cell) for each type, according to the state of infection
at the end of follow-up (cleared or persistent), it was
observed that the median for HPV-31 type in the group
of women where clearance was found (median = 332.5;
IQR = 12,399.72) was greater than the median for
those where this virus was not cleared (median = 9.4;
IQR = 1,659.98, p = 0.0450). There were no differences
in any of the groups regarding the medians for the other
HR-HPV types.
The change in colposcopy findings was also evaluated
concerning the result at the start of follow-up and the
result at the moment of clearance, or at the end of
follow-up (Figure 3). There were statistically significant
differences regarding HPV-16 concerning absolute values
for viral loads for each group, since the value for the
group which became worse regarding diagnosis by colpos-
copy was lower (median = 89,300; IQR = 253,600) than
Figure 2 Persistence rates for the 6 HR-HPV types. BL: baseline; 1st FU: first follow-up; 2nd FU: second follow-up; 3rd FU: third follow-up.
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that for the other groups (improved: median = 2.9 × 106;
IQR = 1.1 × 107; alike: median = 2.9 × 106; IQR = 9.9 × 106)
(p = 0.046). There were no differences in the rest of the
types evaluated here regarding viral load according to
change in colposcopy findings.
When evaluating normalised viral load according to
the degree of HPV infection and colposcopy findings at
the start and end of follow-up, it was found that median
viral load for HPV-58 was greater for women who had a
better prognosis (median = 3.98; IQR = 351.9) compared
Table 4 Determinants of clearance for the most prevalent HR-HPV types
Time independent variables HPV-16 HPV-18 HPV-45 HPV-58
Multivariable
model HR (95% CI)
Multivariable
model HR (95% CI)
Multivariable model
Tm R (95% CI)
Multivariable model
Tm R (95% CI)
Age >50 0.99 (0.53-1.86) 0.59 (0.18-1.87) 1.13 (0.63-2.02) 0.94 (0.63-1.38)
35-50 1.14 (0.66-1.96) 0.79 (0.35-1.75) 0.77 (0.49-1.20) 1.26 (0.89-1.79)
<35 Reference Reference Reference Reference
City Other city 2.58 (1.51-4.4) 1.21 (0.51-2.9) 0.97 (0.62-1.52) 1.79 (1.33-2.39)
Bogota Reference Reference Reference Reference
Ethnicity Afrodescendant 2.35 (0.69-7.93) 0.85 (0.11-6.61) 0.42 (0.16-1.12) -
Mestizo Reference Reference Reference Reference
Other* - - - 1.17 (0.47-2.89)
Contraceptive method No method 1.01 (0.65-1.59) 0.75 (0.33-1.73) 0.84 (0.56-1.27) 0.98 (0.73-1.30)
Hormonal 1.45 (0.72-2.96) 1 (0.35 -2.9) 0.76 (0.45-1.26) 0.97 (0.54-1.72)
Other Reference Reference Reference Reference
Lifetime sexual partners 1 1.24 (0.83-1.86) 1.2 (0.61-2.51) 1.05 (0.72-1.52) 1.10 (0.84-1.44)
>1 Reference Reference Reference Reference
Age at first Intercourse ≥18 0.93 (0.6-1.41) 1.08 (0.53-2.19) 1.23 (0.85-1.77) 1.13 (0.85-1.51)
<18 Reference Reference Reference Reference
Coinfection Yes 0.87 (0.46-1.65) 2.49 (0.54-11.45) 1.06 (0.46-2.45) 0.87 (0.58-1.32)
No Reference Reference Reference Reference
Viral Load** Low 2.1 (0.87-5.15) 0.48 (0.08-2.93) 1.27 (0.76-2.12) 1.36 (0.81-2.29)
Middle 1.49 (0.64-3.51) 0.74 (0.24-2.27) 1.61 (1.01-2.57) 1.04 (0.61-1.78)
High Reference Reference Reference Reference
*Since only 2 women of other ethnicity had HPV-58 (1 Afrodescendant and 1 Indigenous) they were put in a category “Other”, just for this type.
**Low viral load meant a viral load below 9.99E + 5, middle 1.00E + 6 to 9.99E + 9 and high meant a viral load higher than 1.00E + 10.
Values in bold = p < 0.05.
HPV Human papillomavirus, CI Confidence interval, HR Hazard ratio, Tm R Time ratio.
Figure 3 Change in colposcopy results for the 6 HR-HPV types studied here.
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to those whose prognosis remained the same (alike)
(mean = 0.013; IQR = 0 .68), only in the group of women
having persistence for this virus (p = 0.012).
The number of reinfections for each viral type was de-
termined (Table 3); HPV-58 was the only viral type for
which there were no reinfection events during the time
follow-up lasted.
Discussion
This study has provided detailed epidemiological data
for six HR-HPV types present in a Colombian cohort.
This has been the first study in Colombia (to the best of
our knowledge) aimed at using real time quantification
of DNA from the 6 most prevalent types of HR-HPV,
giving absolute and normalised load values.
Findings concerning the virus’ persistence for the 6
types included here have demonstrated that the risk of
acquiring a later HPV infection becomes increased in
women already infected by any type of HPV (regardless
of complying with a phylogenetic relationship [23],
mainly between high risk types [24,25]). Such coinfection
could have been the result of immune system deficiency
regarding clearance, thereby facilitating viral persistence at
the infection site [25].
Regarding the state of infection (single or multiple)
and its relationship to clearance time, this work did not
reveal an important relationship between such aspects.
Various studies have shown that type specific HPV
clearance seems to occur regardless of coinfection in
an immunocompetent population [26,27].
The highest clearance rates in our cohort were observed
for HPV-33 and HPV-16. Previous reports have shown
that HPV-16 clears out after other HR-HPV types
[26,28,29], but in or study, this type of infection displayed
a more transient pattern. Our results are in agreement
with previous studies showing that the majority of women
with a type-specific infection are negative for that particu-
lar viral after one year [19,30].
The reduced clearance rates observed for infections
with HPV-18 and −31 types is particularly important
bearing in mind that HPV-31 was found in high
prevalence in our country [4] and that HPV-18 has
been detected in aggressive forms of cancer [31].
Despite HPV-31 was not evaluated in the multivariable
model due to the low sample size, it is worth noting that
it displayed the highest viral load values and one of the
lowest clearance rates. Future studies analysing more
women infected with this viral type might help to a better
understanding about the influence of viral loads in the
type-specific clearance process.
HPV-16, −18 and −58 viral load values did not have a
clear relationship with clearance time. This has already
been shown for a population from Bogotá in a study
involving semi-quantitative identification of viral DNA
[24]. The present study showed that, regardless of using a
more sensitive technique, no relationship was established
between viral load and clearance time for these types, not
just in Bogotá, but also in other Colombian cities.
Another factor associated with clearance time was city
of origin, showing that women infected by types from
the A9 species became cleared more rapidly if they came
from Girardot/Chaparral. It is supposed that these cities
have factors related to sexual behaviour or cultural char-
acteristics which were not measured in this study and
which would have modulated such findings. When analys-
ing the control arm of the large randomised PATRICIA
study, it was found that region of origin was one of the
behavioural determinants of clearance time, as north-
American women took less time to clearance than their
European counterparts [20].
Regarding ethnicity, fine control was not used for
obtaining it; thus, other ethnic characteristics which
were not controlled in this study may have intervened in
such marked association between city and clearance
time. Another aspect concerned the women’s nutritional
state; most women were from low socio-economic strata.
However, nutritional and/or feeding data was not con-
trolled and may have provided more detailed characteris-
tics concerning the population’s idiosyncrasies. Previous
studies have shown that women who consumed one or
more servings of vegetables per day cleared their HPV in-
fections more quickly than women who did not consume
vegetables daily [32]. The intake of lower levels of micro-
nutrients found in vegetables has been associated with in-
creased persistence [33].
Other factor that was not measured in this study but
that could influence HPV clearance is hygienic practices.
In a cohort of university students, it has been shown
that the use of tampons was associated with a reduced
rate of HR-HPV clearance [32].
Very interesting data for three A9 species types
(HPV-16, −31 and −58) was revealed when determin-
ing viral load according to the state of infection and
colposcopy findings since these had low viral load
values (absolute or per cell) associated with greater le-
sion severity at the end of follow-up or when infection
did not become eliminated. Besides intermediate viral
load values for HPV-45 (A7 species) were associated
with faster time to clearance, this may be a factor related
to transient infection. Such results could have been due to
immune system evasion mechanisms since it has been
reported that low HPV viral load values have been related
to persistent infection [34] and it could be suggested that
higher viral load values could be detected efficiently by
the immune system and rapidly eliminated.
This is contradictory with studies proposing that high
viral loads facilitate persistence, specifically, it has been
shown that HPV-16 viral loads in LSIL and HSIL were
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higher compared with no intraepithelial lesion or ma-
lignancy [35].
This work has several strengths, such as having com-
piled data from two important focuses of HPV infections
(i.e. Girardot and Bogotá), determined viral load using the
most sensitive technique for doing so and the percentage
of multiple infections revealing an important Colombian
populational characteristic. However, the study had diffi-
culties in terms of follow-up times, since infection transi-
ence meant that shorter follow-up times than the ones
established here may probably have led to obtaining more
precise clearance and incidence values. Our information
was limited to using prevalent high risk infections for
analysing persistence and clearance of infection; the
foregoing means that follow-up studies are needed to
facilitate understanding the most prevalent epidemio-
logical HPV patterns for Colombia.
Diagnosing HPV infection in clinical specimens has
been widely accepted to date in Colombia; viral DNA
identification in this type of sample has been included in
the Obligatory Healthcare Plan, 2012. The following step
must thus be to incorporate monitoring from the iden-
tification of HPV infection in cervical cancer control
schemes. Such work thus contributes towards the search
for a correct algorithm for defining HPV DNA screening
since the time taken for most women to clear the virus
must be determined for calculating the determinants of
such scheme and be referred to regular monitoring [19].
Conclusions
Time to clearance in Colombian females infected by the
most frequently occurring HR-HPV types in the sample
population was not modulated by infection status (single
or multiple). However, viral load played a role in terms
of infection regarding HPV-45 and the origin of HPV-16
and −58 infection. Viral persistence and worsening of
cytological findings were related to lower HPV-16, −31
and −58 viral loads. All women in our sample who
eliminated HPV-58 were not infected again by this
viral type. Given that time to clearance was related to
lesion development, such information should prove
significant when designing HPV DNA primary screening
in Colombian healthcare systems, as well as in developing
countries.
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